According to the Zhitong Finance App, iFLYTEK (02506) announced its 2026 interim results, with operating revenue of about 446 million yuan, up 49.4% year on year; gross profit of about 236 million yuan, up 53.5% year on year; net loss attributable to owners of the parent company was 59.03 million yuan, down 20% year on year.
In the first half of 2026, the company actively expanded its market, and its customer base continued to grow. As of June 30, 2026, the company provided products and services to more than 77,000 primary medical institutions, covering 828 districts and counties in 31 provinces, and more than 700 grade hospitals. The broad market coverage fully proves the technological leadership of the company's AI medical products, market competitiveness and efficiency of the company's marketing system, and lays a solid foundation for the next rapid development of the company's business.
In order to adapt to the company's medium- to long-term strategic development direction, focus on improving the quality and efficiency of AI medical core business, and further optimize resource allocation, the company integrated and upgraded its four major business lines into three business segments: AI Diagnosis and Treatment Assistant, AI Health Assistant, and AI Digital Foundation. Among them: “AI Diagnosis and Treatment Assistant” undertakes the original primary solution and hospital solution business; “AI Health Assistant” corresponds to the patient management service business; and the “AI digital base” corresponds to the regional solution business.
In the first half of 2026, the company completed an iterative software upgrade for the core product “Xingyao” and launched a new “Xingyao Pro” to further optimize the hearing experience and intelligent adaptation capabilities. As of June 30, 2026, smart hearing aids have set up about 60 offline brand image stores and more than 400 cooperative stores, building an integrated online and offline marketing channel, and channel synergy continues to increase.